Integral Diagnostics (IDX.AX)

Overall impact
B (71)

Commentary

Integral Diagnostics is a strong overall performer. With a 'B' rating of 71.3 for overall impact (84th percentile compared to all companies), Integral Diagnostics ranks 285th out of 668 industry peers, behind Curium Pharma, Allena Pharmaceuticals, Pluristem Therapeutics and 281 others, and ahead of Kadmon, Madrigal Pharmaceuticals, 4Sc AG and 380 others. On top material causes for Integral Diagnostics's industry (Biotechnology), Integral Diagnostics performs well in Accountable Institutions (95.2 score), Child and Maternal Health (90.7), Child and Maternal Health (90.7) and 20 other causes where it received an 'A' score and performs poorly in Improved Mental Health (35.4 score), Sustainable Use of Water (33.9) and Improved Mental Health (35.4).
Screens
Fur
Impact
Cause IDX.AX
Peer rank
Overall impact

Log in to view this information

Screens
Fur
Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
3,000
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Vic, Australia
Share classes
IDX.AX
Description
Integral Diagnostics Limited, a healthcare services company, engages in the provision of diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand. It provides positron emission tomography, magnetic resonance imaging, and other radiology services. The company was founded in 1967 and is headquartered in Melbourne, Australia.
Material causes
Ethos considers the following causes material for Integral Diagnostics, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.